A Chinese company suing Apple for patent infringement appears to be virtually non-existent.
Known as Shenzhen Baili Marketing Services, the company filed a lawsuit against Apple in 2014, claiming that the iPhone 6 and 6S looked too much like its 100C phone. Baili wanted a ban placed on iPhone 6 sales in Beijing, something the capital city’s intellectual property regulator was prepared to do. But Apple filed an appeal, which means the iPhone 6 lineup remains on sale in Beijing.
Phone calls to Baili, which is owned by Chinese smartphone manufacturer Digione, were unanswered, according to the Wall Street Journal. Baili’s websites no longer exist. And visits by the Journal to the three registered locations turned up no company offices.
Further, Baili and Digione are both broke as their debt is greater than their overall assets. Digione’s collapse was the result of “buggy products, mismanagement and fierce competition,” former employees and investors told the Journal.The lack of any obvious presence is just the latest wrinkle in the bizarre case that has wrapped up Apple in yet another patent infringement case. The lawsuit highlights the tough environment Apple faces in China, which also ruled earlier this year that Apple doesn’t own the rights to the iPhone trademark.Despite its lack of presence, Baili is “still operational in its necessary functions,” and will continue to fight Apple in court, Digione lawyer Andy Yang told the Journal. Baili may even think about escalating its lawsuit to include the iPhone 6S and iPhone 6S Plus, Yang added. But with its appeal in place, Apple needn’t worry about a ban on iPhone sales in Beijing, at least not for now.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas